News
![2 High-Yield Dividend Stocks to Buy Now and Hold for a Decade or Longer: https://g.foolcdn.com/editorial/images/751708/stock-market-trader-at-home-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODI1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--31389748b29c194771215cebc2cbcdee503e017c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/stock-market-trader-at-home-getty.jpg?locale=us)
2 High-Yield Dividend Stocks to Buy Now and Hold for a Decade or Longer
These days, finding dividend payers that offer eye-popping yields is as easy as clicking the sort button on your favorite stock screener. Unfortunately, the vast majority of stocks that float to the
![Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today: https://g.foolcdn.com/editorial/images/751969/person-in-a-lab-looking-through-a-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUs1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--28a32f774ad605298683874feeac8c702b484e2e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-in-a-lab-looking-through-a-microscope.jpg?locale=us)
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
Hardly for the first time this year, biotech CymaBay Therapeutics (NASDAQ: CBAY) had a winning day on the market Monday. Following the news that its leading drug candidate had been granted an
![Why Revolution Medicines Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/751899/scientist-with-head-down.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemU1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9d0810e2d495d79046d32ad33223c9e6a291e4d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-with-head-down.jpg?locale=us)
Why Revolution Medicines Stock Is Crashing Today
Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from
![3 Stocks Cathie Wood Is Buying That Should Be on Your List Too: https://g.foolcdn.com/editorial/images/751770/dna-genetic-sequencing-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHU0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--013ecba2a0144aae52ef19fd91cbd7715edb4198/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech-1.jpg?locale=us)
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA), Block (NYSE: SQ), and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have
![AT&T Just Raised Its Free-Cash-Flow Guidance. Here's Why It Should Still Suspend Its Dividend.: https://g.foolcdn.com/editorial/images/751648/person-makes-phone-call-while-looking-at-information-on-a-tablet.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUc0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67f613a7d7a2c4a30f3e6145e6bd67c3926b60a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-makes-phone-call-while-looking-at-information-on-a-tablet.jpg?locale=us)
AT&T Just Raised Its Free-Cash-Flow Guidance. Here's Why It Should Still Suspend Its Dividend.
AT&T (NYSE: T) may finally have begun a long-awaited rebound. The stock surged 7% higher following its earnings announcement for the third quarter of 2023. A possible reason for the increase may
![3 Unstoppable Stocks to Buy Sooner Rather Than Later: https://g.foolcdn.com/editorial/images/751591/scientists-happy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEM0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5efa253d45499b801832952a91db435d7605df73/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-happy.jpg?locale=us)
3 Unstoppable Stocks to Buy Sooner Rather Than Later
Some stocks have the "it" factor. They've got such tremendous growth prospects that investors want to add them to their portfolios without any hesitation.
Three Motley Fool investors think they've
![Pfizer Just Announced Layoffs. Should You Still Buy the Stock?: https://g.foolcdn.com/editorial/images/751579/investor-considers-papers-at-a-cafe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3kzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--994a579e7f31c2a047a19fb55c77dfc83eb02c9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-papers-at-a-cafe.jpg?locale=us)
Pfizer Just Announced Layoffs. Should You Still Buy the Stock?
On October 13, Pfizer (NYSE: PFE) served up a platter of bad news for investors. Aside from lowering its estimates for sales of its jab and its antiviral pill for COVID, the company reported that
![3 Safe Dividend Stocks to Beat Inflation: https://g.foolcdn.com/editorial/images/751608/chain-and-padlock-wrapped-around-stack-of-100-dollar-bills-cash-money-locked-up.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0czYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--532c20c5beb029f0de58c47dc2a4efd84ad2819c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chain-and-padlock-wrapped-around-stack-of-100-dollar-bills-cash-money-locked-up.jpg?locale=us)
3 Safe Dividend Stocks to Beat Inflation
Like it or not, inflation remains higher than Americans have been accustomed to, and the impacts of last year's price surge have not gone away. As of September, inflation as measured by the Consumer
![If You Had Invested $10,000 in AT&T in 2013, This Is How Much You Would Have Today: https://g.foolcdn.com/editorial/images/749506/att-t-growth-stock-market-investment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0czYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f1076e1635b427d647f12850e45d3cea7ee2176c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att-t-growth-stock-market-investment.jpg?locale=us)
If You Had Invested $10,000 in AT&T in 2013, This Is How Much You Would Have Today
AT&T (NYSE: T) has a history dating back to the late 1800s. And over many periods of that long and storied history, it's been a fantastic stock to own.
However, over the last 10 years, AT&T stock
![Where Will AT&T Stock Be in 1 Year?: https://g.foolcdn.com/editorial/images/751680/att_retail_chicago.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUszYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--500555c64283148694cbcaf16dbeebd64b0e3303/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att_retail_chicago.jpg?locale=us)
Where Will AT&T Stock Be in 1 Year?
AT&T's (NYSE: T) stock rallied nearly 7% on Oct. 19 after the telecom giant posted its third-quarter earnings report. Its revenue rose 1% year over year to $30.35 billion and surpassed analysts'
![Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?: https://g.foolcdn.com/editorial/images/751646/jazz-pharma.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHkzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--147009d804bdbcaa7b5f4f01f83d6f944288a8b7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/jazz-pharma.jpg?locale=us)
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock
![Is Pfizer a Bad News Buy Right Now?: https://g.foolcdn.com/editorial/images/751705/gettyimages-1203044156.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNyszYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--93f19c8a79ab5ac1e2697592a3c9c779df46454d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1203044156.jpg?locale=us)
Is Pfizer a Bad News Buy Right Now?
Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine
![Why AT&T Stock Was Gaining Today: https://g.foolcdn.com/editorial/images/751737/5g-cellular-communications-tower.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNG0zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bef7b37fbfc6ca9e41f5dfd7ed66ecb27d9b4414/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5g-cellular-communications-tower.jpg?locale=us)
Why AT&T Stock Was Gaining Today
Shares of AT&T (NYSE: T) were gaining for the second day in a row today as a flurry of positive analyst notes gave the stock another boost. As of 1:37 p.m. ET, the stock was up 1.5% after gaining as
![Why Knight-Swift Transportation Stock Popped Today: https://g.foolcdn.com/editorial/images/751717/truck-warehouse-loading-dock.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNE8zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--907017b85d57aad3d83db2a78bcd3fdc6bcc506d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/truck-warehouse-loading-dock.jpg?locale=us)
Why Knight-Swift Transportation Stock Popped Today
Shares of Knight-Swift Transportation (NYSE: KNX) were moving higher today after the diversified transportation company topped analyst estimates in its third-quarter earnings report.
As of 11:27
![AT&T Stock: Is the Worst Finally Over?: https://g.foolcdn.com/editorial/images/751634/att-5g.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXEzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--46d7bec5943cd1fd5bdaebd2270e222ee5445e2f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att-5g.jpg?locale=us)
AT&T Stock: Is the Worst Finally Over?
If you had to choose a stock for the investing hall of shame over the last decade, AT&T (NYSE: T) would be a good candidate.
It's made two of the worst acquisitions of this century, spending more
![It's Not Too Late to Buy AT&T Stock After a Stellar Earnings Report: https://g.foolcdn.com/editorial/images/751598/5g-sunset-cell-tower.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzYzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a2210d8abe22a4f02566ea327cbf6759e65d9217/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5g-sunset-cell-tower.jpg?locale=us)
It's Not Too Late to Buy AT&T Stock After a Stellar Earnings Report
Telecom giant AT&T (NYSE: T) surprised investors on Thursday with third-quarter results that sent its stock flying. Not only did AT&T beat analyst expectations for both revenue and earnings per
![Why Summit Materials Stock Jumped on Thursday: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaTRFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--7b1053a3605f66e35a9c178293b2594f08cb4204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tmf-logo_400x400.png?locale=us)
Why Summit Materials Stock Jumped on Thursday
Shares of Summit Materials (NYSE: SUM) were up 8% as of 11:30 a.m. ET on Thursday after the construction materials provider filed a preliminary statement with the Securities and Exchange Commission
![AT&T; (T) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
AT&T; (T) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
AT&T (NYSE: T)Q3 2023 Earnings CallOct 19, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![3 Under-the-Radar Biotech Stocks to Buy in 2023: https://g.foolcdn.com/editorial/images/751195/dnaphoto.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3UxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--89d740104227ca3513bad03ac5cc81e940de3638/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dnaphoto.jpg?locale=us)
3 Under-the-Radar Biotech Stocks to Buy in 2023
Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --
![Is AbbVie Stock Too Pricey to Touch Right Now?: https://g.foolcdn.com/editorial/images/751190/two-scientists-work-at-lab-bench-with-scope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzIxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--46678908b0153154a16e81e57a8194713c1c3539/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-scientists-work-at-lab-bench-with-scope.jpg?locale=us)
Is AbbVie Stock Too Pricey to Touch Right Now?
For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. Why is the market
![CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada)
The updated release reads:
AURINIA PHARMACEUTICALS TO RELEASE THIRD QUARTER FINANCIAL AND
![Pfizer and Moderna Don't See Eye to Eye on This 1 Particular Point: https://g.foolcdn.com/editorial/images/751377/gettyimages-1295986889.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelMxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cbefdba653482f7fbf5c915470e4791efa750152/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1295986889.jpg?locale=us)
Pfizer and Moderna Don't See Eye to Eye on This 1 Particular Point
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been in agreement on a lot since the beginning of the pandemic. They both recognized the importance of eventually launching combined vaccines --
![Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Abbott Laboratories (NYSE: ABT)Q3 2023 Earnings CallOct 18, 2023, 9:00 a.m. ET
Operator
Source Fool.com
![Why Ardelyx Stock Popped Today: https://g.foolcdn.com/editorial/images/751438/retired-man-undergoing-chemotherapy-cancer-health-sick.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3EwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--569f85831cb58b56dd749914b775449e67ef8f4c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/retired-man-undergoing-chemotherapy-cancer-health-sick.jpg?locale=us)
Why Ardelyx Stock Popped Today
Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press
![Is Exelixis Stock a Buy Now?: https://g.foolcdn.com/editorial/images/750752/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTIwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ede03e9e6f9b068581c4903ffbc375b469b90840/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
Is Exelixis Stock a Buy Now?
Exelixis (NASDAQ: EXEL) is not exactly a household name in the biotech industry, but that hasn't stopped the company from crushing the market this year -- rising over 30%. Perhaps one key reason